Catabasis
Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage drug
development company built on a pathway pharmacology technology platform,
today announced that Catabasis will present a company overview at the
Wedbush PacGrow Healthcare Conference. The Wedbush PacGrow Healthcare
Conference will be held August 11 - 12, 2015, in New York, NY at Le
Parker Meridien Hotel.
-
Jill C. Milne, Ph.D., chief executive officer, will present Catabasis
corporate and pipeline updates on August 11, 2015, at 10:20am local
time at Le Parker Meridien.
A webcast of the presentation will be available in the Investors section
of the Company’s website, www.catabasis.com,
and will be archived for 30 days following the presentation.
About Catabasis
Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of novel
therapeutics using its proprietary Safely Metabolized And Rationally
Targeted, or SMART, linker technology platform. The Company's SMART
linker technology platform is based on the concept of treating diseases
by simultaneously modulating multiple targets in one or more related
disease pathways. The Company engineers bi-functional product candidates
that are conjugates of two molecules, or bioactives, each with known
pharmacological activity, joined by one of its proprietary SMART
linkers. The SMART linker conjugates are designed for enhanced efficacy
and improved safety and tolerability. The Company’s focus is on
treatments for rare diseases. The Company is also developing other
product candidates for the treatment of serious lipid disorders. For
more information on the Company's technology and pipeline of drug
candidates, please visit www.catabasis.com.
About CAT-1004
CAT-1004 is an oral small molecule that inhibits activated NF-kB, a
protein that coordinates cellular response to muscular damage, stress
and inflammation and plays an important role in muscle health. In
skeletal muscle, activated NF-kB drives muscle degeneration and
suppresses muscle regeneration. In animal models of DMD, CAT-1004
inhibited activated NF-kB, reduced muscle inflammation and degeneration
and increased muscle regeneration. In Phase 1 clinical trials, CAT-1004
inhibited activated NF-kB and was well-tolerated with no observed safety
concerns. The FDA has granted CAT-1004 orphan drug and fast track
designations for the treatment of DMD.
About CAT-2054
CAT-2054 is an investigational oral drug initially being developed for
the treatment of hypercholesterolemia in patients for whom existing
therapies are insufficient. By modulating the SREBP pathway, CAT-2054
may inhibit production of important cholesterol metabolism proteins such
as PCSK9, HMG-CoA reductase, ATP citrate lyase and NPC1L1. If approved,
CAT-2054, may have the potential to be the first therapy to
simultaneously modulate cholesterol synthesis, clearance and absorption.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150804005345/en/
Copyright Business Wire 2015